YS company's HBV patent valuation through reopening auction
On September 15, 2023, YS Biopharma increased by 9% and reached a point of control (POC) at a value of one dollar per share. The market value of this company was 86.580 million dollars before the reopening due to the publication of the news, after which it stabilized at 94.372 million dollars; Therefore, according to this method, the value of the accepted patent on HBV hepatitis vaccine was equal to 7.792 million dollars based on the mechanism of supply, demand and according to buyers on the company's stock board.
On September 15, 2023, YS Biopharma increased by 9% and reached a point of control (POC) at a value of one dollar per share. The market value of this company was 86.580 million dollars before the reopening due to the publication of the news, after which it stabilized at 94.372 million dollars; Therefore, according to this method, the value of the accepted patent on HBV hepatitis vaccine was equal to 7.792 million dollars based on the mechanism of supply, demand and according to buyers on the company's stock board.